A version of this manuscript was presented at the Association of Public Policy Analysis and Management Fall Research Conference in Denver, Colorado, November 8, 2019. Rebecca Myerson received support for her work on this article from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health; the Office of the Director, National Institutes of Health; and the National Cancer Institute (NCI) under Award No. K12HD101368. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Myerson received grant funding for investigator-initiated research from Bristol-Myers Squibb from 2018 to 2019. Samuel Crawford has equity holdings with Gilead, Amgen, Allogene, and Bluebird Bio. Laura Wherry received support for her work on this article from a grant under the Robert Wood Johnson Foundation’s Policies for Action program. The authors acknowledge the PRAMS Working Group and the Centers for Disease Control and Prevention for assistance in accessing and interpreting the PRAMS data. They are grateful to Koray Caglayan and participants in the 2019 Association for Public Policy Analysis and Management fall research conference for helpful discussions, and to Jiren Sun for excellent research assistance.